Article

Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: Role of tumor necrosis factor-α

Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA.
Journal of Neurochemistry (Impact Factor: 4.24). 03/2006; 96(3):706-18. DOI: 10.1111/j.1471-4159.2005.03566.x
Source: PubMed

ABSTRACT Activated microglia are implicated in the pathogenesis of disease-, trauma- and toxicant-induced damage to the CNS, and strategies to modulate microglial activation are gaining impetus. A novel action of the tetracycline derivative minocycline is the ability to inhibit inflammation and free radical formation, factors that influence microglial activation. Minocycline is therefore being tested as a neuroprotective agent to alleviate CNS damage, although findings so far have yielded mixed results. Here, we showed that administration of a single low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or methamphetamine (METH), a paradigm that causes selective degeneration of striatal dopaminergic nerve terminals without affecting the cell body in substantia nigra, increased the expression of mRNAs encoding microglia-associated factors F4/80, interleukin (IL)-1alpha, IL-6, monocyte chemoattractant protein-1 (MCP-1, CCL2) and tumor necrosis factor (TNF)-alpha. Minocycline treatment attenuated MPTP- or METH-mediated microglial activation, but failed to afford neuroprotection. Lack of neuroprotection was shown to be due to the inability of minocycline to abolish the induction of TNF-alpha and its receptors, thereby failing to modulate TNF signaling. Thus, TNF-alpha appeared to be an obligatory component of dopaminergic neurotoxicity. To address this possibility, we examined the effects of MPTP or METH in mice lacking genes encoding IL-6, CCL2 or TNF receptor (TNFR)1/2. Deficiency of either IL-6 or CCL2 did not alter MPTP neurotoxicity. However, deficiency of both TNFRs protected against the dopaminergic neurotoxicity of MPTP. Taken together, our findings suggest that attenuation of microglial activation is insufficient to modulate neurotoxicity as transient activation of microglia may suffice to initiate neurodegeneration. These findings support the hypothesis that TNF-alpha may play a role in the selective vulnerability of the nigrostriatal pathway associated with dopaminergic neurotoxicity and perhaps Parkinson's disease.

Download full-text

Full-text

Available from: Diane Miller, Oct 08, 2014
0 Followers
 · 
67 Views
  • Source
    • "The legend for the different cell types and phenotypes is provided at the bottom. provided contrasting, model-dependent results, about the contribution of innate inflammation to the acute neurodegeneration of dopaminergic neurons in the SN (Sriram and others 2006; Wu and others 2002). Systemic inflammation , induced by administering IL-1β, was shown to impact the survival of dopaminergic neurons in the 6OHDA model, providing clear evidence of the influence of immune-to-brain communication on the progression of PD (Pott Godoy and others 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The study of the dynamics and functions of microglia in the healthy and diseased brain is a matter of intense scientific activity. The application of new techniques and new experimental approaches has allowed the identification of novel microglial functions and the redefinition of classic ones. In this review, we propose the study of microglial functions, rather than their molecular profiles, to better understand and define the roles of these cells in the brain. We review current knowledge on the role of surveillant microglia, proliferating microglia, pruning/neuromodulatory microglia, phagocytic microglia, and inflammatory microglia and the molecular profiles that are associated with these functions. In the remodeling scenario of microglial biology, the analysis of microglial functional states will inform about the roles in health and disease and will guide us to a more precise understanding of the multifaceted roles of this never-resting cells.
    The Neuroscientist 04/2014; 21(2). DOI:10.1177/1073858414530512 · 7.62 Impact Factor
  • Source
    • "Unfortunately, given ibudilast's multiple actions including its ability to inhibit release of multiple cytokines and chemokines, its inhibition of MIF and PDE, and its promotion of GDNF, the precise mechanism responsible for its success or failure will be difficult to identify. Minocycline also has its own multiplicity of effects including its antibiotic, anti-inflammatory and neuroprotective effects (Cui et al., 2008; Garrido-Mesa et al., 2013; Soczynska et al., 2012; Sriram et al., 2006) making interpretation regarding its specific mechanism equally challenging. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Glia (including astrocytes, microglia, and oligodendrocytes), which constitute the majority of cells in the brain, have many of the same receptors as neurons, secrete neurotransmitters and neurotrophic and neuroinflammatory factors, control clearance of neurotransmitters from synaptic clefts, and are intimately involved in synaptic plasticity. Despite their prevalence and spectrum of functions, appreciation of their potential general importance has been elusive since their identification in the mid-1800s, and only relatively recently have they been gaining their due respect. This development of appreciation has been nurtured by the growing awareness that drugs of abuse, including the psychostimulants, affect glial activity, and glial activity, in turn, has been found to modulate the effects of the psychostimulants. This developing awareness has begun to illuminate novel pharmacotherapeutic targets for treating psychostimulant abuse, for which targeting more conventional neuronal targets has not yet resulted in a single, approved medication. In this chapter, we discuss the molecular pharmacology, physiology, and functional relationships that the glia have especially in the light in which they present themselves as targets for pharmacotherapeutics intended to treat psychostimulant abuse disorders. We then review a cross section of preclinical studies that have manipulated glial processes whose behavioral effects have been supportive of considering the glia as drug targets for psychostimulant-abuse medications. We then close with comments regarding the current clinical evaluation of relevant compounds for treating psychostimulant abuse, as well as the likelihood of future prospects.
    Advances in pharmacology (San Diego, Calif.) 01/2014; 69:1-69. DOI:10.1016/B978-0-12-420118-7.00001-9
  • Source
    • "[34] "
Show more